DXRX vs. AGL, YGEN, ABDX, GDR, PRM, VRCI, GENI, DMTR, LLAI, and LLA
Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), Proteome Sciences (PRM), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.
Diaceutics vs.
ANGLE (LON:AGL) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.
Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.
ANGLE received 168 more outperform votes than Diaceutics when rated by MarketBeat users. However, 88.24% of users gave Diaceutics an outperform vote while only 62.46% of users gave ANGLE an outperform vote.
In the previous week, ANGLE's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.
18.8% of ANGLE shares are held by institutional investors. Comparatively, 52.4% of Diaceutics shares are held by institutional investors. 16.2% of ANGLE shares are held by company insiders. Comparatively, 34.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ANGLE currently has a consensus price target of GBX 40, suggesting a potential upside of 335.73%. Diaceutics has a consensus price target of GBX 160, suggesting a potential upside of 35.02%. Given ANGLE's higher probable upside, equities analysts clearly believe ANGLE is more favorable than Diaceutics.
Summary
Diaceutics beats ANGLE on 11 of the 15 factors compared between the two stocks.
Get Diaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Diaceutics Competitors List
Related Companies and Tools
This page (LON:DXRX) was last updated on 4/27/2025 by MarketBeat.com Staff
Buy DXRX Stock Free DXRX Stock Alerts